Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-08

Clinical Trial Update: Risperdal Consta for Bipolar Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Risperdal Consta for Bipolar I Disorder has completed, and the trial results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: University of Pittsburgh | Conditions: Bipolar I Disorder | Phase 3 | Status: COMPLETED | Results posted: 2016-02-08